BGB149 is a first-in-class function blocking antibody with potent pre-clinical anti-tumour activity. The fully humanised antibody is anticipated to enter the clinic towards the end of 2018.
Selective AXL inhibitors
Footer
Get In Touch
BerGenBio ASA
Company registration number 992 219 688
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159 (general) + 47 535 01 564 (urgent medical enquiries)